CSI Market
Sign In | Register

Sensei Biotherapeutics Inc (SNSE) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access SNSE Annual Cash Flow →
Tracking cash flow results across Sensei Biotherapeutics Inc to Jun 30 2025 helps illustrate how Jun 30 2026's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-186.24
Depreciation & amortization0.05
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation17.38
Income (Loss) from Equity Method Investments0.00
Fair Value of Assets Acquired145.38
Embedded Derivative Gain Loss On Embedded Derivative Net-
Finance Lease Interest Expense-
Interest On Capital Lease-
Operating Lease Right Of Use Asset Amortization Expense0.38
Finance Lease Right Of Use Asset Amortization0.00
Marketable Securities Realized Gain Loss-
Increase Decrease In Operating Lease Liabilities-0.41
Accretion On Marketable Securities-0.08
Finance Lease Impairment Loss-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Employee Related Liabilities-0.11
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.25
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense-10.36
Other Working Capital-0.14
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities7.38
Discontinued operations0.00
Net Cash flow from Operating Activities-26.41
Investing Activities
Capital Expenditures-0.01
Sale of Capital Items0.00
Short-term Investments Proceeds-145.96
Short-term Investments Acq.0.00
Real Estate Investments0.00
Capital Proceeds Relating To Property And Equipment-
Insurance Proceeds Relating To Property And Equipment-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired6.46
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-139.50
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-15.78
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock200.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.08
Proceeds From Exercise Of Common Stock Warrants And Options-
Finance Lease Principal Payments-0.06
Proceeds From Issuance Of Common Stock Upon Initial Public Offering Net Of Issuance Costs-
Capital Expenditures Incurred But Not Yet Paid-
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction-
Noncash Interest On Financing-
Stock Issued-
Conversion Of Stock Amount Converted-
Employee Stock Purchase Plan Expense-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities184.14
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-26.41
Total Cash Flow18.24
4 historic quarters locked

Sign in to unlock the full Sensei Biotherapeutics Inc cash flow history.

Sign In Create Free Account

About Faeth Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-331562

Figures are derived from filed reports and may be restated. Historical data is subject to revision.